Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04834869 · ClinicalTrials.gov registry record

COVID-19 Vaccines Safety Tracking (CoVaST)

A clinical trial of COVID-19 Vaccine and Adverse Reaction to Vaccine, sponsored by Masaryk University.

Recruiting
Registry status
30,000
Enrollment target
14
Study locations

NCT04834869: Recruiting study of COVID-19 Vaccine and Adverse Reaction to Vaccine, sponsored by Masaryk University.

NCT04834869 is a study of COVID-19 Vaccine and Adverse Reaction to Vaccine that is actively recruiting participants, run by Masaryk University. The registered enrollment target is 30,000 participants, above the 893-participant average among 6 other COVID-19 Vaccine trials with a reported enrollment target (3259% higher). The trial reports 14 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04834869, a study of COVID-19 Vaccine and Adverse Reaction to Vaccine, is actively recruiting participants, sponsored by Masaryk University.

RECRUITING
Registry status
30,000 participants
Enrollment target
14
Study locations

Study Summary

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

Primary Outcome

Dichotomous outcome for the emergence of local side effects (e.g. injection site pain, injection site swelling, and injection site redness)

Conditions Studied

COVID-19 Vaccine Adverse Reaction to Vaccine

Interventions

  • BIOLOGICAL BNT162b2
  • BIOLOGICAL mRNA-1273
  • BIOLOGICAL AZD1222
  • BIOLOGICAL CoronaVac
  • BIOLOGICAL Sinopharm

Study Locations (14)

Other

  • University of Split - Split
  • Masaryk University - Brno
  • University of Tartu - Tartu
  • Jimma University - Jimma
  • Justus-Liebig University Giessen - Giessen
  • University of Ghana - Accra
  • Sinaloa's Pediatric Hospital - Culiacán
  • Medical University of Silesia - Katowice
  • Nursing School of Coimbra - Coimbra
  • Irkutsk Scientific Center of Siberian Branch of Russian Academy of Sciences - Irkutsk
  • University of Belgrade - Belgrade
  • University of Ljubljana - Ljubljana

Pennsylvania

  • American College of Physicians - Philadelphia

Ontario

  • McMaster University - Hamilton

Trial Details

FieldValue
Enrollment Target 30,000 participants
Start Date 2021-04-01
Est. Completion 2026-12-31
Masaryk University

1 total trials

What NCT04834869 shows while recruiting

NCT04834869 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 893-participant average among 6 other COVID-19 Vaccine trials with a reported enrollment target (3259% higher).

The record links to 2 conditions, with COVID-19 Vaccine appearing as the primary indexed condition, and to 5 interventions - of which BNT162b2 is the first listed.

NCT04834869 lists 14 locations in 3 states (Other, Pennsylvania, Ontario).

Frequently Asked Questions

What is clinical trial NCT04834869 about?

NCT04834869 is a clinical study titled "COVID-19 Vaccines Safety Tracking (CoVaST)". This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteach...

What is the current status of trial NCT04834869?

This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2021-04-01. Estimated completion is 2026-12-31.

What conditions does trial NCT04834869 study?

This clinical trial studies the following conditions: COVID-19 Vaccine, Adverse Reaction to Vaccine.

What interventions are being tested in trial NCT04834869?

The interventions under investigation include: BNT162b2 (BIOLOGICAL), mRNA-1273 (BIOLOGICAL), AZD1222 (BIOLOGICAL), CoronaVac (BIOLOGICAL), Sinopharm (BIOLOGICAL).

Who is sponsoring clinical trial NCT04834869?

This trial is sponsored by Masaryk University, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04834869 being conducted?

This trial has 14 study locations across Pennsylvania, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19 Vaccine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00684580 · 30,000 participants

    Protocol For Collecting Data On Patients With Childhood Cancer

  • NCT03053193 · 30,000 participants

    MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

  • NCT03689595 · 30,000 participants

    Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

  • NCT05484804 · 30,000 participants · NA

    Accountability for Care Through Undoing Racism & Equity for Moms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04834869

Source: ClinicalTrials.gov NCT04834869, the US trial registry maintained by the National Library of Medicine. NCT04834869 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.